Atlas Trials

Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer

Clinical trial NCT06518837 · RECRUITING

Trial details

NCT number
NCT06518837
Sponsor
Rutgers, The State University of New Jersey
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Hormone Receptor-Positive Breast CancerHER2-Negative Breast Cancer
Start date
2024-10-30
Primary completion
2027-09-30
Enrollment
40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.